(Q43258660)

17 November 2017

title

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients (English)

1 reference

17 November 2017

0 references

invasive aspergillosis

1 reference

2

1 reference

17 November 2017

C Viscoli

1

1 reference

17 November 2017

H Akan

3

1 reference

17 November 2017

L Baila

4

1 reference

17 November 2017

A Sonet

5

1 reference

17 November 2017

A Gallamini

6

1 reference

17 November 2017

A Giagounidis

7

1 reference

17 November 2017

O Marchetti

8

1 reference

17 November 2017

R Martino

9

1 reference

17 November 2017

L Meert

10

1 reference

17 November 2017

M Paesmans

11

1 reference

17 November 2017

L Ameye

12

1 reference

17 November 2017

M Shivaprakash

13

1 reference

17 November 2017

A J Ullmann

14

1 reference

17 November 2017

J Maertens

15

1 reference

17 November 2017

Infectious Disease Group of the EORTC

16

1 reference

17 November 2017

language of work or name

English

0 references

publication date

19 October 2009

1 reference

Journal of Antimicrobial Chemotherapy

17 November 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

17 November 2017

volume

64

1 reference

17 November 2017

issue

6

1 reference

17 November 2017

page(s)

1274-1281

1 reference

Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Factors associated with overall and attributable mortality in invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP355

21 January 2018

Identifiers

DOI

10.1093/JAC/DKP355

1 reference

17 November 2017

1 reference